Durveqtix%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520gene%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520therapy

# Durveqtix gene therapy ## Overview Durveqtix (dihydro)), a gene therapy, is a one-time intravenous infusion indicated for the treatment of patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency). It delivers a functional gene encoding for human coagulation factor VIII (FVIII). ## Primary Indications Treatment of hemophilia A in adult and pediatric patients 12 years of age and older. ## Adult Dosing A single intravenous infusion of Durveqtix is administered. The dose is 6 x 10^13 vector genomes per kilogram (vg/kg) of body weight. ## Pediatric Dosing For patients 12 years of age and older, the dose is the same as in adults: 6 x 10^13 vg/kg. Dosing for pediatric patients younger than 12 years of age has not been established. ## Dose Adjustments No dose adjustments are necessary based on renal or hepatic impairment. However, caution is advised in patients with severe hepatic impairment. ## Contraindications * Hypersensitivity to the active substance or any of the excipients. * Use of B-domain deleted FVIII concentrates within 7 days prior to administration. ## Adverse Effects The most common adverse reactions reported in clinical trials include: * Elevated liver enzymes (ALT, AST) * Headache * Infusion-related reactions (e.g., pyrexia, chills, nausea, vomiting) * Muscle spasms * Peripheral edema * Nosebleeds (epistaxis) * Joint swelling (hemarthrosis) A serious risk is the development of FVIII inhibitors. ## Key Drug Interactions * **B-domain deleted FVIII concentrates:** Avoid concurrent use. If a patient requires FVIII replacement therapy within 7 days prior to Durveqtix administration, it should be a full-length FVIII concentrate. * **Immunosuppressants:** Concomitant use of immunosuppressants may be necessary to mitigate the risk of immune responses against the viral vector or FVIII. Specific guidance on immunosuppression should follow local protocols. * **Corticosteroids:** May be used to manage immune-mediated reactions. ## Monitoring * **Factor VIII activity levels:** Monitor FVIII activity levels to assess response and guide management. * **Liver function tests:** Monitor ALT and AST regularly, particularly in the first few weeks and months post-infusion. * **Inhibitor screening:** Monitor for the development of FVIII inhibitors. * **Infusion-related reactions:** Monitor for signs and symptoms of infusion-related reactions during and after the infusion. ## Clinical Pearls * Durveqtix is a one-time infusion. * Patients should be monitored for at least 90 days post-infusion for potential adverse events, including liver enzyme elevations and inhibitor development. * The long-term durability and safety profile are still being evaluated. * Patients should avoid concomitant use of B-domain deleted FVIII concentrates. *** *Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant literature for complete details and to verify the information provided.*